Related Experiment Video
Updated: Nov 5, 2025
07:30
Assessing Insulin Clearance in Mice via In Situ Liver Perfusion
Published on: December 13, 2024
536
Insulin therapy; a valuable legacy and its future perspective.
1Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Chemistry, National Cheng Kung University, Tainan 701, Taiwan..
International Journal of Biological Macromolecules
|May 14, 2021
Summary
This article reviews human therapeutic insulin, a protein-based drug. It covers insulin
Area of Science:
- Biochemistry
- Pharmaceutical Science
- Materials Science
Background:
- Proteins and peptides are increasingly utilized in pharmaceuticals due to their high efficacy and low side effects.
- The pharmaceutical protein and peptide drug industry began in 1982 with the introduction of insulin.
- The demand for protein and peptide therapeutics is growing annually.
Purpose of the Study:
- To provide a comprehensive overview of human therapeutic insulin.
- To explore the historical development of insulin as a therapeutic agent.
- To discuss current and future applications of insulin therapy.
Main Methods:
- Historical review of insulin's introduction and development.
- Discussion of current insulin therapy methodologies.
- Exploration of future treatment potentials for insulin.
Main Results:
- Human therapeutic insulin has a significant history dating back to 1982.
- Current insulin therapies offer improved treatment options.
- Future research promises advanced applications for insulin treatments.
Conclusions:
- Insulin remains a cornerstone therapeutic protein with a rich history.
- Ongoing advancements in insulin therapy continue to benefit patients.
- The future of insulin treatment holds potential for further innovation.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
662
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
662
01:16Insulin: Dosing Regimen and Adverse Effects
355
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
355
01:28Insulin: The Receptor and Signaling Pathways
1.9K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.9K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
739
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
739
01:27Insulin Formulations: Types and Delivery
353
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
353
01:22Diabetes Mellitus: Overview and Type I Subtype
4.1K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.1K